Thank you, Allan. In accordance with the rules regarding the presentation of discontinued operations, the assets, liabilities, and activities of Infusionz along with certain manufacturing operations and Interactive Offers have been reclassified as discontinued operations for all periods presented. The reclassification of Infusionz and related operations along with Interactive's reduced our sales by approximately $4.066 million and $21.520 million for the years 2023 and 2022 respectively, and is excluded from the following comparison of operations during the years ended June 30, 2023 and 2022. Revenue increased by $57.611,165 million or 250% for the fiscal year ended June 30, 2023, compared with the fiscal year ended June 30, 2022. $41.041,341 million or 71% of the increase was related to the acquisitions of the Lucky Tail brand and E-Core Technologies, Inc., the 2023 acquisitions and approximately 33% or $18.848,230 million was related to the acquisitions of Cygnet Online, LLC and VitaMetica, the 2022 acquisitions. Compared to the prior year period this was offset by a decline in other businesses of approximately 4%. Cost of revenue increased by $38.922 million or 475% compared to the fiscal year ended June 30, 2020. $31.144 million of this or 88% of the increase was related to the 2023 acquisitions and approximately $8.640 million or 22% was related to the 2022 acquisitions. The gross profit overall increased by $18.688 million. The gross margin decline of approximately 22% to 42% compared to 64% in the prior year was related to the sales from the re-commerce business versus the sales of branded products. Management expects the gross margin to improve as the branded product segment continues to grow as a percentage of the overall sales and we continue to gain economies of scale in our purchasing of products. Sales and marketing expense increased by approximately $5.259 million, or 103% compared to the same period last year. $2.396 million of this or 46% of the increase was related to the 2023 acquisitions and fractionally $1.373 million of this increase, or 26% was related to the 2022 acquisitions. There was an increase of approximately $1.4 million or 28% related to the other businesses. The increase in sales and marketing was primarily related to the acquisitions and increased expenditures for brand and company awareness. However, management has aligned the marketing expenditures with expected growth strategy to decrease the overall percentage of sales and marketing to cost. Distribution costs increased $10.155 million or $459,000, compared to the same period last year. $1.850 million or 18% of this increase was related to the 2023 acquisitions, and approximately $7.306 million or 72% of the increase related to the 2022 acquisitions and the rest of the business. There continues to be an increase in transportation costs and third party provider rates. Management has implemented strategies to change promotions, increased prices, and adjust packaging overall to decrease the distribution costs to sales, and is in the process of consolidating distribution centers including closing the California facility as of July 1, 2023. General and administrative expenses increased by approximately $400,000 or 4% compared to the same year, the prior year. General and administrative expenses increased by $2.332 million from 2023 acquisitions with the remainder of the business had a decrease in general and administrative expenses of approximately $1.928 million. Management has actively been reducing general and administrative costs by consolidating administrative functions and capitalizing the overall size of the company. Management will continue to implement these strategies to decrease the percentage of general and administrative expenses when compared to total sales. Other operating expenses increased by $3.9 million or 80% with the same period as last year. These expenses are primarily non-cash expenses, increased based on intangible assets, created with the acquisitions and continued amortization of stock compensation. $1.612 million or 41% was related to the 2023 acquisitions of acquired intangible assets and $1.616 or 41% of the increase was related to the 2022 acquisitions, amortization of acquisitions, intangible assets. The remaining increase of approximately $700,000 was related to increased stock-based compensation and depreciation. Other expenses increased by approximately $11 million, which is primarily the loss recognized on the sale of the Infusionz and related assets and the reserves against the amounts owed to the company from the buyers, the impairment of Interactive Offers intangible assets, and an increase in the interest expense, both on acquisition debt and the termination of the $15 million senior debt facility on October 1, 2022. Management estimates the cash paid for interest for the year ended June 30, 2024, to be approximately $1.4 million. The loss from discontinued operations of Interactive Offers was $1.729 million and $1.160 million for the years ended June 30, 2023, and 2022 respectively. The loss from discontinued operations of Infusionz and the related businesses was approximately $338,000 for the year ended June 30, 2023, and income of $4.9 million for the year ended June 30, 2022. The company had net losses of approximately $16.930 million compared to net losses of approximately $2.1 million in the prior year. The increase in net losses is primarily related to the above mentioned items which was offset by the net loss attributed to the non-controlling interest of our consolidated subsidiaries. On June 30, 2023, the company had cash of approximately $4.4 million, working capital of $5.8 million and availability on the line of credit of $6 million. And on September 30 2023 the line had over $9.8 million of availability. At this time, I'd like to open up the call for questions. Operator?